Search results for "LUMA"

showing 10 items of 227 documents

Spatiaalisen ikkunoinnin ja sokean signaalinerottelun menetelmien hyödyntäminen MEG-aineiston analysoinnissa

2018

Sokean signaalinerottelun menetelmät ovat käyttökelpoisia magnetoenkefalografilla mitattujen aivomagneettikäyrien analysoinnissa. Sokean signaalinerottelun menetelmien avulla voidaan selvittää, mistä aivoaktivaatio on peräisin ja millaisiin toimintoihin aktivaatio voidaan yhdistää. MEG-aineiston ajallinen tarkkuus on hyvä, joten lyhytkin mittausaika tuottaa hyvin suuren aineiston. Suuren aineiston tuottamat laskennalliset ongelmat voidaan kiertää ikkunoimalla MEG-aineisto aika- tai tilasuunnassa. Aineiston ikkunointia on sovellettu aiemmissa tutkimuksissa toiminnallisen magneettikuvauksen aineistoon, jolloin ikkunointi on tehty aikasuunnassa. Tässä tutkielmassa ikkunointia sovellettiin MEG-…

MEGtoisen asteen lähde-erottelumallit (SOS)riippumattomien komponenttien analyysi (ICA)sokea signaalinerottelu (BSS)simulointiaivotutkimus
researchProduct

Decoding the Folding of Burkholderia glumae Lipase: Folding Intermediates En Route to Kinetic Stability

2012

The lipase produced by Burkholderia glumae folds spontaneously into an inactive near-native state and requires a periplasmic chaperone to reach its final active and secretion-competent fold. The B. glumae lipase-specific foldase (Lif) is classified as a member of the steric-chaperone family of which the propeptides of alpha-lytic protease and subtilisin are the best known representatives. Steric chaperones play a key role in conferring kinetic stability to proteins. However, until present there was no solid experimental evidence that Lif-dependent lipases are kinetically trapped enzymes. By combining thermal denaturation studies with proteolytic resistance experiments and the description of…

Macromolecular AssembliesProtein StructureProtein FoldingBurkholderiaProtein ConformationStereochemistryBiophysicslcsh:MedicineBiochemistryProtein Chemistrybacterial lipasemolten globuleBacterial ProteinsNative stateBurkholderia glumaeLipaseProtein Interactionslcsh:ScienceBiologyMultidisciplinarybiologylipase-specific foldasePhysicslcsh:RSubtilisinProteinsLipasebiology.organism_classificationMolten globuleEnzymesChaperone ProteinsKineticsBiochemistryChaperone (protein)Enzyme StructureProteolysisFoldasebiology.proteinlcsh:Qsteric chaperoneProtein foldingnear-native folding intermediateResearch ArticleMolecular Chaperones
researchProduct

Carry-over effects of conditions at the wintering grounds on breeding plumage signals in a migratory bird : roles of phenotypic plasticity and select…

2016

To understand the consequences of ever-changing environment on the dynamics of phenotypic traits, distinguishing between selection processes and individual plasticity is crucial. We examined individual consistency/plasticity in several male secondary sexual traits expressed during the breeding season (white wing and forehead patch size, UV reflectance of white wing patch and dorsal melanin coloration) in a migratory pied flycatcher (Ficedula hypoleuca) population over an 11-year period. Furthermore, we studied carry-over effects of three environmental variables (NAO, a climatic index; NDVI, a vegetation index; and rainfall) at the wintering grounds (during prebreeding moult) on the expressi…

Male0106 biological sciences0301 basic medicinePopulation010603 evolutionary biology01 natural sciencesUV reflectancesecondary sexual traitdifferential mortality03 medical and health sciencesAnimalssexual selectionPasseriformesSelection GeneticeducationEcology Evolution Behavior and SystematicsPhenotypic plasticityeducation.field_of_studybiologyEcologyReproductionFicedulaMicroevolutionPhenotypic traitFeathersbiology.organism_classificationseasonal interactionsmelaninmicroevolutionPhenotype030104 developmental biologyclimate changeNatural population growthPlumageSexual selectionta1181SeasonsJournal of Evolutionary Biology
researchProduct

Exome Analysis Reveals Genomic Markers Associated with Better Efficacy of Nivolumab in Lung Cancer Patients

2019

Abstract Purpose: Immune checkpoint inhibitors revolutionized the treatment of non-small cell lung cancer (NSCLC). However, only one-quarter of patients benefit from these new therapies. PD-L1 assessment and tumor mutational burden (TMB) are available tools to optimize use of checkpoint inhibitors but novel tools are needed. Exome sequencing could generate many variables but their role in identifying predictors of response is unknown. Experimental Design: We performed somatic and constitutional exome analyses for 77 patients with NSCLC treated with nivolumab. We studied: one-tumor-related characteristics: aneuploidy, CNA clonality, mutational signatures, TMB, mutations in WNT, AKT, MAPK, an…

Male0301 basic medicineCancer ResearchLung NeoplasmsDNA repairAntineoplastic AgentsPembrolizumabAntibodies Monoclonal HumanizedB7-H1 AntigenDisease-Free Survival03 medical and health sciencesAntineoplastic Agents Immunological0302 clinical medicineCarcinoma Non-Small-Cell LungExome SequencingBiomarkers TumorHumansMedicineCTLA-4 AntigenLung cancerExomeExome sequencingAgedRetrospective StudiesAged 80 and overbusiness.industryGenomicsMiddle Agedmedicine.diseaseIpilimumabNivolumabTreatment Outcome030104 developmental biologyOncology030220 oncology & carcinogenesisMutationMonoclonalCancer researchBiomarker (medicine)FemaleNivolumabbusinessClinical Cancer Research
researchProduct

Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort…

2021

BackgroundCheckpoint inhibitors revolutionized the treatment of metastatic melanoma patients. Although tumor burden and lactate dehydrogenase (LDH) are associated with overall survival (OS), the impact of tumor growth kinetics remains elusive and in part contradictory. The aims of this study were to develop a novel simple and rapid method that estimates pretreatment metastatic growth rate (MGR) and to investigate its prognostic impact in melanoma patients treated with antiprogrammed death receptor-1 (PD-1) antibodies.MethodsMGR was assessed in three independent cohorts of a total of 337 unselected consecutive metastasized stage IIIB–IV melanoma patients (discovery cohort: n=53, confirmation…

Male0301 basic medicineOncologyCancer ResearchSkin NeoplasmsTime Factors2437Programmed Cell Death 1 ReceptorPembrolizumabMetastasis0302 clinical medicineRisk FactorsImmunotherapy BiomarkersImmunology and Allergy1506Immune Checkpoint InhibitorsRC254-282MelanomaNeoplasms. Tumors. Oncology. Including cancer and carcinogensMiddle Agedddc:EuropeNivolumabTreatment OutcomeOncology030220 oncology & carcinogenesisCohortMolecular MedicineFemaleimmunotherapyNivolumabCohort studytumormedicine.medical_specialtyImmunologyAntibodies Monoclonal HumanizedRisk Assessment03 medical and health sciencesPredictive Value of TestsInternal medicinemelanomamedicineHumansCell ProliferationNeoplasm StagingRetrospective StudiesPharmacologyProportional hazards modelbusiness.industrybiomarkersReproducibility of Resultsmedicine.disease030104 developmental biologyTomography X-Ray ComputedbusinessBrain metastasis
researchProduct

The international WAO/EAACI guideline for the management of hereditary angioedema – the 2017 revision and update

2018

Hereditary Angioedema (HAE) is a rare and disabling disease. Early diagnosis and appropriate therapy are essential. This update and revision of the global guideline for HAE provides up-to-date consensus recommendations for the management of HAE. In the development of this update and revision of the guideline, an international expert panel reviewed the existing evidence and developed 20 recommendations that were discussed, finalized and consented during the guideline consensus conference in June 2016 in Vienna. The final version of this update and revision of the guideline incorporates the contributions of a board of expert reviewers and the endorsing societies. The goal of this guideline up…

MaleAftercare32 Biomedical and Clinical SciencesLanadelumabC1-inhibitorDiseaseGuidelineRecommendations0302 clinical medicinePregnancyDiagnosisImmunology and Allergy030212 general & internal medicinePrecision MedicineChildHereditary angioedemaConsensus conferenceSelf-administrationManagementGRADEHereditary angioedemaFemaleComplement C1 Inhibitor ProteinQuality of lifeAdultPulmonary and Respiratory Medicinemedicine.medical_specialtyWhat treatmentConsensusAdolescentHealth Planning GuidelinesImmunologyMEDLINEDysfunctional family7.3 Management and decision makingYoung Adult03 medical and health sciencesRare DiseasesQuality of life (healthcare)Clinical ResearchTerminology as TopicIndividualized therapymedicineHumansLactationFinal versionProphylaxisbusiness.industryPreventionAngioedemas HereditaryGuidelinePrecision medicinemedicine.disease3211 Oncology and Carcinogenesis030228 respiratory systemFamily medicineTherapybusiness7 Management of diseases and conditions
researchProduct

In vivo molecular imaging of the GABA/benzodiazepine receptor complex in the aged rat brain

2012

The GABA-ergic system, known to regulate neural tissue genesis during cortical development, has been postulated to play a role in cerebral aging processes. Using in vivo molecular imaging and voxel-wise quantification, we aimed to assess the effects of aging on the benzodiazepine (BDZ) recognition site of the GABA A receptor. To visualize BDZ site availability, [C-11]-flumazenil microPET acquisitions were conducted in young and old rats. The data were analyzed and region of interest analyses were applied to validate the voxel-wise approach. We observed decreased [C-11]-flumazenil binding in the aged rat brains in comparison with the young control group. More specifically, clusters of reduce…

MaleFlumazenilReceptor complexCerebellumAgingHippocampusMolecular imagingMidbrainGABAmedicineRadioligandAnimalsReceptorBenzodiazepineChemistryGeneral NeuroscienceBrainReceptors GABA-ACortex (botany)Molecular ImagingRatsmedicine.anatomical_structurenervous systemFlumazenilPositron emission tomography (PET)Neurology (clinical)Geriatrics and GerontologyNeuroscienceDevelopmental Biologymedicine.drugProtein Binding
researchProduct

Free-choice ethanol consumption under the influence of GABAergic drugs in rats.

2002

Background: Neurobiological mechanisms leading from controlled alcohol consumption to addiction are poorly understood. Among multiple neurotransmitters γ-amino-butyric acid (GABA) is suggested to play a role. The present investigation studied effects of drugs interacting with the GABAergic system on the motivation of ethanol consumption. Methods: Fifty male PVG/OlaHsd rats were analyzed for free-choice ethanol drinking behavior without and with pre-exposure to drugs acting on the GABAergic system. For pretreatment, animals received the benzodiazepine agonists or antagonists diazepam, flumazenil, or Ro15-4513, or the GABA uptake inhibitor tiagabine via the drinking water for 4 weeks (day −21…

MaleTiagabineAlcohol Drinkingmedicine.drug_classNipecotic AcidsMedicine (miscellaneous)Administration OralPharmacologyToxicologyChoice BehaviorGABA Antagonistschemistry.chemical_compoundReceptors GABAmedicineGABA transporterAnimalsTiagabineGABA AgonistsBenzodiazepineEthanolbiologybusiness.industryRatsPsychiatry and Mental healthchemistryFlumazenilbiology.proteinGABAergicReuptake inhibitorbusinessDiazepammedicine.drugAlcoholism, clinical and experimental research
researchProduct

New-onset third-degree atrioventricular block because of autoimmune-induced myositis under treatment with anti-programmed cell death-1 (nivolumab) fo…

2017

There has been considerable progress in treating malignant melanoma over the last few years. The immune-checkpoint-inhibitors nivolumab and pembrolizumab have been approved by the Food and Drug Administration in 2014 for the therapy of metastatic melanoma. Anti-programmed cell death-1-blocking antibodies are known to cause immune-related adverse events. Physicians should be aware of common and rare side effects and pay attention to new ones. We therefore report a severe and life-threatening side effect of anti-programmed cell death-1 immunotherapy with nivolumab that has not been previously reported: the development of a third-degree atrioventricular block. After a second infusion with nivo…

MaleUveal NeoplasmsOncologyCancer Researchmedicine.medical_specialtyMyocarditisSide effectDermatologyPembrolizumab030204 cardiovascular system & hematologyAutoimmune Diseases03 medical and health sciencesAntineoplastic Agents ImmunologicalFatal Outcome0302 clinical medicineInternal medicineHumansMedicineAtrioventricular BlockMelanomaMyositisMyositisbusiness.industryThird-degree atrioventricular blockMelanomaAntibodies MonoclonalMiddle Agedmedicine.diseaseNivolumabOncology030220 oncology & carcinogenesisImmunologyNivolumabbusinessAtrioventricular blockMelanoma Research
researchProduct

First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (C…

2021

First-line chemotherapy for advanced or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastro-oesophageal junction adenocarcinoma has a median overall survival (OS) of less than 1 year. We aimed to evaluate first-line programmed cell death (PD)-1 inhibitor-based therapies in gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma. We report the first results for nivolumab plus chemotherapy versus chemotherapy alone.In this multicentre, randomised, open-label, phase 3 trial (CheckMate 649), we enrolled adults (≥18 years) with previously untreated, unresectable, non-HER2-positive gastric, gastro-oesophageal junction, or oesophageal adenocarcinoma, …

Malemedicine.medical_specialtyEsophageal Neoplasmsmedicine.medical_treatmentIpilimumabAdenocarcinoma030204 cardiovascular system & hematologyGastroenterologyCapecitabine03 medical and health sciences0302 clinical medicineStomach NeoplasmsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumans030212 general & internal medicineProgression-free survivalImmune Checkpoint InhibitorsAgedChemotherapybusiness.industryGeneral MedicineMiddle Agedmedicine.diseaseProgression-Free SurvivalOxaliplatinNivolumabFluorouracilAdenocarcinomaDrug Therapy CombinationFemaleEsophagogastric JunctionNivolumabbusinessmedicine.drugThe Lancet
researchProduct